Findings

What do systematic reviews say?

577 questions · 585 findings · 77 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 143 · 24.4%GRADE not reported 26 · 4.4%Very low 145 · 24.8%Low 156 · 26.7%Moderate 98 · 16.8%High 17 · 2.9%

Active treatment vs observation

FEV1 % predicted: absolute change from baseline · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen

1 finding from 1 review

Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 58 participants
Very low

Rilonacept vs placebo

Prevention of AA amyloidosis · people with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ImmunoGuard vs placebo

Prevention of AA amyloidosis · people with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anakinra vs placebo

Prevention of AA amyloidosis · people with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Canakinumab vs placebo

Prevention of AA amyloidosis · people with colchicine‐resistant familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine single dose vs divided dose

Prevention of AA amyloidosis · children with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine (oral) vs placebo

Prevention of AA amyloidosis · people with familial Mediterranean fever

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Exercise vs ACBT

FEV1 % predicted: absolute change from baseline · adolescents and adults with cystic fibrosis

1 finding from 1 review

Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Exercise plus PD&P vs PD&P only

Participant preference · children and young adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Exercise vs underwater PEP (uPEP; also known

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Exercise vs underwater PEP (uPEP; also known

Participant preference: VAS test and a questionnaire to evaluate acceptability of technique to participants · adults and children with cystic fibrosis

1 finding from 1 review

Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Very low

Exercise vs ACBT

Participant preference: VAS score for treatment effectiveness and preference. · adolescents and adults with cystic fibrosis

1 finding from 1 review

Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Exercise plus PD&P vs PD&P only

FEV1 % predicted: absolute change from baseline · children and young adults with CF

1 finding from 1 review

Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 55 participants
Very low

Short‐acting inhaled beta‐2 agonists vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 67 participants
Very low

Short‐acting inhaled muscarinic antagonists vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FVC (% predicted) compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 100 participants
Very low

Short‐acting inhaled muscarinic antagonists vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled muscarinic antagonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Very low

Dornase alfa vs placebo or no dornase alfa treatment

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

2 findings from 1 review

Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 320 participants
Moderate
Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 647 participants
High